Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute

Yoo,Koo Han; Lim,Tae Joon; Chang,Sung-Goo

doi:10.3892/etm.2011.400

February 2012 Volume 3 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February 2012 Volume 3 Issue 2

Full Size Image

Article

Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute

Authors:
- Koo Han Yoo
- Tae Joon Lim
- Sung-Goo Chang
View Affiliations / Copyright

Affiliations: Department of Urology, School of Medicine, Kyung Hee University, Seoul, Republic of Korea
Pages: 221-225
|
Published online on: December 1, 2011

https://doi.org/10.3892/etm.2011.400
Expand metrics +

Abstract

Intravesical bacillus Calmette-Guérin (BCG) therapy is the standard prophylaxis for recurrence of non-muscle-invasive bladder cancer (NMIBC). The aim of this study was to confirm the recurrence- and progression-preventing efficacy and safety of 12 times monthly BCG maintenance therapy for NMIBC. This study included 126 patients diagnosed with Ta, T1 and carcinoma in situ bladder cancer between January 2000 and December 2009. Thirty‑four patients in the no maintenance group received a single 6-week course of intravesical immunotherapy after transurethral resection of the bladder tumor (TUR-BT). Ninety-two patients in the maintenance group received a 12-month course after a single 6-week course of intravesical immunotherapy. Recurrence, progression and side effects were assessed. End-points were recurrence-free survival (RFS), progression-free survival (PFS) and disease-specific survival (DSS). The estimated median RFS was 87 months (95% CI 53.0-120.9) in the maintenance group and 48 months (95% CI 0-96.8) in the no maintenance group (log-rank test; P=0.002). The 2-year cumulative RFS rates were 77.3% in the maintenance group and 52.6% in the no maintenance group. Median PFS and DSS were not estimable in both groups. The 2-year cumulative PFS rates were 91.1% in the maintenance group and 80.5% in the no maintenance group (log-rank test; P=0.178). The 2-year cumulative DSS rates were 97.7% in the maintenance group and 91.4% in the no maintenance group (log-rank test; P=0.111). The overall side effects were 40.2% in the maintenance group and 44.1% in the no maintenance group. Monthly maintenance immunotherapy appears to increase RFS rates in high-risk NMIBC. Further study is required to evaluate the efficacy of BCG monthly maintenence for increasing the PFS rate.

View Figures

View References

1.	A JemalF BrayMM CenterJ FerlayE WardD FormanGlobal cancer statisticsCA Cancer J Clin616990201110.3322/caac.20107
2.	S AldousariW KassoufUpdate on the management of non-muscle invasive bladder cancerCan Urol Assoc J45664201020165581
3.	A MoralesD EidingerAW BruceIntracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumorsJ Urol1161801831976820877
4.	DL LammBA BlumensteinJD CrissmanMaintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group StudyJ Urol16311241129200010.1016/S0022-5347(05)67707-510737480
5.	HW HerrDD WartingerWR FairHF OettgenBacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year follow-upJ Urol1471020102319921552578
6.	V PansadoroP EmiliozziL DefidioBacillus Calmette-Guerin in the treatment of stage T1 grade 3 transitional cell carcinoma of the bladder: long-term resultsJ Urol15420542058199510.1016/S0022-5347(01)66692-87500457
7.	MD ShelleyMD MasonH KynastonIntravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analysesCancer Treat Rev36195205201010.1016/j.ctrv.2009.12.00520079574
8.	RJ SylvesterMA van derDL LammIntravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trialsJ Urol16819641970200210.1016/S0022-5347(05)64273-5
9.	A BohlePR BockIntravesical bacille Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumor progressionUrology63682687200410.1016/j.urology.2003.11.049
10.	RA BadalamentHW HerrGY WongA prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of superficial bladder cancerJ Clin Oncol54414491987
11.	MA HudsonTL RatliffDP GillenEO HaaffSM DresnerWJ CatalonaSingle course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trialJ Urol1382952981987
12.	H AkazaS KameyamaT KakizoeAblative and prophylactic effects of BCG Tokyo 172 strain for intravesical treatment in patients with superficial bladder cancer and carcinoma in situ of the bladder. Bladder cancer BCG Study GroupNippon Hinyokika Gakkai Zasshi831831891992(In Japanese).
13.	J PalouP LagunaF Millan-RodriguezRR HallJ Salvador-BayarriJ Vicente-RodriguezControl group and maintenance treatment with bacillus Calmette-Guerin for carcinoma in situ and/or high grade bladder tumorsJ Urol16514881491200110.1016/S0022-5347(05)66333-111342902
14.	H KogaS OzonoT TsushimaMaintenance intravesical bacillus Calmette-Guerin instillation for Ta, T1 cancer and carcinoma in situ of the bladder: randomized controlled trial by the BCG Tokyo Strain Study GroupInt J Urol17759766201010.1111/j.1442-2042.2010.02584.x
15.	S JungSI JungJI ChungBacillus Calmette-Guerin intravesical therapy in superficial bladder cancer: the early experience of comparison of 6 week course and modified 6 3 maintenance therapyKorean J Urol49703708200810.4111/kju.2008.49.8.703
16.	A PawinskiR SylvesterKH KurthA combined analysis of European Organization for Research and Treatment of Cancer, and Medical Research Council randomized clinical trials for the prophylactic treatment of stage TaT1 bladder cancer. European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council Working Party on Superficial Bladder CancerJ Urol156193419411996
17.	DL LammDR RiggsCL TraynelisUO NseyoApparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladderJ Urol15314441450199510.1016/S0022-5347(01)67427-57714962
18.	H AkazaS HinotsuY AsoT KakizoeK KoisoBacillus Calmette-Guerin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder. Four-year results The Bladder Cancer BCG Study GroupCancer7555255919957812924
19.	SG ChangSJ LeeJS HuhJH LeeChanges in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapyOncol Rep8257261200111182036

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Monthly intravesical bacillus Calmette-Guérin maintenance therapy for non-muscle-invasive bladder cancer: 10-year experience in a single institute

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles